secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001787306-21-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis
--------------------------------------------------------------------------------

- Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.
- Submitted NDA to FDA for roflumilast cream for plaque psoriasis based on Phase 3 DERMIS trials.
- Initiated pivotal Phase 3 trial of roflumilast foam in scalp/body psoriasis; topline expected H2 2022.
- Terminated Phase 2a trial of ARQ-252 in vitiligo due to inadequate local drug delivery.
- R&D expense $40.6M vs $32.7M YoY; G&A expense $16.5M vs $5.6M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/0001787306-21-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/arqt-20211104.htm
  HTML page:      https://secwatch.observer/filing/0001787306-21-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer